The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Gene Therapy for Mucopolysaccharidosis-Global Market Insights and Sales Trends 2024
Synopsis
Mucopolysaccharidosis consists of a group of more than 40 genetic disorders that forms a part of lysosomal storage disease. They are caused by an inherited deficiency of an enzyme involved in the degradation of acid glycosaminoglycans (GAGs), which was previously known as mucopolysaccharidosis. All of the mucopolysaccharidoses are rare, autosomal recessive, except for mucopolysaccharidosis III, as it is X-linked.
The global Gene Therapy for Mucopolysaccharidosis market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Gene Therapy for Mucopolysaccharidosis in various end use industries. The expanding demands from the Mucopolysaccharidosis I, Mucopolysaccharidosis II, Mucopolysaccharidosis III A and Mucopolysaccharidosis III B, are propelling Gene Therapy for Mucopolysaccharidosis market. Intravenous, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the ICV segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Gene Therapy for Mucopolysaccharidosis, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Gene Therapy for Mucopolysaccharidosis market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Gene Therapy for Mucopolysaccharidosis market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Gene Therapy for Mucopolysaccharidosis sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Gene Therapy for Mucopolysaccharidosis covered in this report include Sangamo Therapeutics, Swedish Orphan Biovitrum and uniQure, etc.
The global Gene Therapy for Mucopolysaccharidosis market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Sangamo Therapeutics
Swedish Orphan Biovitrum
uniQure
Global Gene Therapy for Mucopolysaccharidosis market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Gene Therapy for Mucopolysaccharidosis market, Segment by Type:
Intravenous
ICV
Intracerebral
Intracisternal
Global Gene Therapy for Mucopolysaccharidosis market, by Application
Mucopolysaccharidosis I
Mucopolysaccharidosis II
Mucopolysaccharidosis III A
Mucopolysaccharidosis III B
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Gene Therapy for Mucopolysaccharidosis companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Mucopolysaccharidosis consists of a group of more than 40 genetic disorders that forms a part of lysosomal storage disease. They are caused by an inherited deficiency of an enzyme involved in the degradation of acid glycosaminoglycans (GAGs), which was previously known as mucopolysaccharidosis. All of the mucopolysaccharidoses are rare, autosomal recessive, except for mucopolysaccharidosis III, as it is X-linked.
The global Gene Therapy for Mucopolysaccharidosis market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Gene Therapy for Mucopolysaccharidosis in various end use industries. The expanding demands from the Mucopolysaccharidosis I, Mucopolysaccharidosis II, Mucopolysaccharidosis III A and Mucopolysaccharidosis III B, are propelling Gene Therapy for Mucopolysaccharidosis market. Intravenous, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the ICV segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Gene Therapy for Mucopolysaccharidosis, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Gene Therapy for Mucopolysaccharidosis market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Gene Therapy for Mucopolysaccharidosis market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Gene Therapy for Mucopolysaccharidosis sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Gene Therapy for Mucopolysaccharidosis covered in this report include Sangamo Therapeutics, Swedish Orphan Biovitrum and uniQure, etc.
The global Gene Therapy for Mucopolysaccharidosis market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Sangamo Therapeutics
Swedish Orphan Biovitrum
uniQure
Global Gene Therapy for Mucopolysaccharidosis market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Gene Therapy for Mucopolysaccharidosis market, Segment by Type:
Intravenous
ICV
Intracerebral
Intracisternal
Global Gene Therapy for Mucopolysaccharidosis market, by Application
Mucopolysaccharidosis I
Mucopolysaccharidosis II
Mucopolysaccharidosis III A
Mucopolysaccharidosis III B
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Gene Therapy for Mucopolysaccharidosis companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Gene Therapy for Mucopolysaccharidosis
1.1 Gene Therapy for Mucopolysaccharidosis Market Overview
1.1.1 Gene Therapy for Mucopolysaccharidosis Product Scope
1.1.2 Gene Therapy for Mucopolysaccharidosis Market Status and Outlook
1.2 Global Gene Therapy for Mucopolysaccharidosis Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Gene Therapy for Mucopolysaccharidosis Market Size by Region (2018-2029)
1.4 Global Gene Therapy for Mucopolysaccharidosis Historic Market Size by Region (2018-2023)
1.5 Global Gene Therapy for Mucopolysaccharidosis Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Gene Therapy for Mucopolysaccharidosis Market Size (2018-2029)
1.6.1 North America Gene Therapy for Mucopolysaccharidosis Market Size (2018-2029)
1.6.2 Europe Gene Therapy for Mucopolysaccharidosis Market Size (2018-2029)
1.6.3 Asia-Pacific Gene Therapy for Mucopolysaccharidosis Market Size (2018-2029)
1.6.4 Latin America Gene Therapy for Mucopolysaccharidosis Market Size (2018-2029)
1.6.5 Middle East & Africa Gene Therapy for Mucopolysaccharidosis Market Size (2018-2029)
2 Gene Therapy for Mucopolysaccharidosis Market by Type
2.1 Introduction
2.1.1 Intravenous
2.1.2 ICV
2.1.3 Intracerebral
2.1.4 Intracisternal
2.2 Global Gene Therapy for Mucopolysaccharidosis Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Gene Therapy for Mucopolysaccharidosis Historic Market Size by Type (2018-2023)
2.2.2 Global Gene Therapy for Mucopolysaccharidosis Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Gene Therapy for Mucopolysaccharidosis Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Gene Therapy for Mucopolysaccharidosis Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Gene Therapy for Mucopolysaccharidosis Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Gene Therapy for Mucopolysaccharidosis Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Gene Therapy for Mucopolysaccharidosis Revenue Breakdown by Type (2018-2029)
3 Gene Therapy for Mucopolysaccharidosis Market Overview by Application
3.1 Introduction
3.1.1 Mucopolysaccharidosis I
3.1.2 Mucopolysaccharidosis II
3.1.3 Mucopolysaccharidosis III A
3.1.4 Mucopolysaccharidosis III B
3.2 Global Gene Therapy for Mucopolysaccharidosis Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Gene Therapy for Mucopolysaccharidosis Historic Market Size by Application (2018-2023)
3.2.2 Global Gene Therapy for Mucopolysaccharidosis Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Gene Therapy for Mucopolysaccharidosis Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Gene Therapy for Mucopolysaccharidosis Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Gene Therapy for Mucopolysaccharidosis Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Gene Therapy for Mucopolysaccharidosis Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Gene Therapy for Mucopolysaccharidosis Revenue Breakdown by Application (2018-2029)
4 Gene Therapy for Mucopolysaccharidosis Competition Analysis by Players
4.1 Global Gene Therapy for Mucopolysaccharidosis Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Gene Therapy for Mucopolysaccharidosis as of 2022)
4.3 Date of Key Players Enter into Gene Therapy for Mucopolysaccharidosis Market
4.4 Global Top Players Gene Therapy for Mucopolysaccharidosis Headquarters and Area Served
4.5 Key Players Gene Therapy for Mucopolysaccharidosis Product Solution and Service
4.6 Competitive Status
4.6.1 Gene Therapy for Mucopolysaccharidosis Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Sangamo Therapeutics
5.1.1 Sangamo Therapeutics Profile
5.1.2 Sangamo Therapeutics Main Business
5.1.3 Sangamo Therapeutics Gene Therapy for Mucopolysaccharidosis Products, Services and Solutions
5.1.4 Sangamo Therapeutics Gene Therapy for Mucopolysaccharidosis Revenue (US$ Million) & (2018-2023)
5.1.5 Sangamo Therapeutics Recent Developments
5.2 Swedish Orphan Biovitrum
5.2.1 Swedish Orphan Biovitrum Profile
5.2.2 Swedish Orphan Biovitrum Main Business
5.2.3 Swedish Orphan Biovitrum Gene Therapy for Mucopolysaccharidosis Products, Services and Solutions
5.2.4 Swedish Orphan Biovitrum Gene Therapy for Mucopolysaccharidosis Revenue (US$ Million) & (2018-2023)
5.2.5 Swedish Orphan Biovitrum Recent Developments
5.3 uniQure
5.3.1 uniQure Profile
5.3.2 uniQure Main Business
5.3.3 uniQure Gene Therapy for Mucopolysaccharidosis Products, Services and Solutions
5.3.4 uniQure Gene Therapy for Mucopolysaccharidosis Revenue (US$ Million) & (2018-2023)
5.3.5 Recent Developments
6 North America
6.1 North America Gene Therapy for Mucopolysaccharidosis Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Gene Therapy for Mucopolysaccharidosis Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Gene Therapy for Mucopolysaccharidosis Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Gene Therapy for Mucopolysaccharidosis Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Gene Therapy for Mucopolysaccharidosis Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Gene Therapy for Mucopolysaccharidosis Market Dynamics
11.1 Gene Therapy for Mucopolysaccharidosis Industry Trends
11.2 Gene Therapy for Mucopolysaccharidosis Market Drivers
11.3 Gene Therapy for Mucopolysaccharidosis Market Challenges
11.4 Gene Therapy for Mucopolysaccharidosis Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
